|
1
|
Chang ET and Adami HO: The enigmatic
epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol
Biomarkers Prev. 15:1765–1777. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yao KT: The application and prospect of
nasopharyngeal carcinoma etiology. China Cancer. 6:3–4. 1997.
|
|
3
|
Lo KW, To KF and Huang DP: Focus on
nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tao Q and Chan AT: Nasopharyngeal
carcinoma: molecular pathogenesis and therapeutic developments.
Expert Rev Mol Med. 9:1–24. 2007.PubMed/NCBI
|
|
6
|
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB,
Thorgeirsson SS and Popescu NC: Cloning, characterization, and
chromosomal localization of a gene frequently deleted in human
liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res.
58:2196–2199. 1998.PubMed/NCBI
|
|
7
|
Durkin ME, Yuan BZ, Zhou X, et al: DLC-1:
a Rho GTPase-activating protein and tumour suppressor. J Cell Mol
Med. 11:1185–1207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lahoz A and Hall A: DLC-1: a significant
GAP in the cancer genome. Genes Dev. 22:1724–1730. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng D, Ren CP, Yi HM, et al: Genetic and
epigenetic alterations of DLC-1, a candidate tumor suppressor gene,
in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai).
38:349–355. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seng TJ, Low JS, Li H, et al: The major
8p22 tumor suppressor DLC1 is frequently silenced by methylation in
both endemic and sporadic nasopharyngeal, esophageal, and cervical
carcinomas, and inhibits tumor cell colony formation. Oncogene.
26:934–944. 2007. View Article : Google Scholar
|
|
11
|
Zhang H, Feng X, Liu W, et al: Underlying
mechanisms for LTF inactivation and its functional analysis in
nasopharyngeal carcinoma cell lines. J Cell Biochem. 112:1832–1843.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou W, Feng X, Li H, et al: Functional
evidence for a nasopharyngeal carcinoma-related gene BCAT1 located
at 12p12. Oncol Res. 16:405–413. 2007.PubMed/NCBI
|
|
13
|
Shao JY, Wang HY, Huang XM, et al:
Genome-wide allelotype analysis of sporadic primary nasopharyngeal
carcinoma from southern China. Int J Oncol. 17:1267–1275.
2000.PubMed/NCBI
|
|
14
|
Song L and Wang H: Study on the tumor
heterogeneity of nasopharyngeal carcinoma cell line (SUNE-1). Chin
J Cancer. 17:324–327. 1998.
|
|
15
|
Kim TY, Lee JW, Kim HP, et al: DLC-1, a
GTPase-activating protein for Rho, is associated with cell
proliferation, morphology, and migration in human hepatocellular
carcinoma. Biochem Biophys Res Commun. 355:72–77. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong CM, Yam JW, Ching YP, et al: Rho
GTPase-activating protein deleted in liver cancer suppresses cell
proliferation and invasion in hepatocellular carcinoma. Cancer Res.
65:8861–8868. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goodison S, Yuan J, Sloan D, et al: The
RhoGAP protein DLC-1 functions as a metastasis suppressor in breast
cancer cells. Cancer Res. 65:6042–6053. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan BZ, Jefferson AM, Millecchia L,
Popescu NC and Reynolds SH: Morphological changes and nuclear
translocation of DLC1 tumor suppressor protein precede apoptosis in
human non-small cell lung carcinoma cells. Exp Cell Res.
313:3868–3880. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ullmannova-Benson V, Guan M, Zhou X, et
al: DLC1 tumor suppressor gene inhibits migration and invasion of
multiple myeloma cells through RhoA GTPase pathway. Leukemia.
23:383–390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loyo M, Brait M, Kim MS, et al: A survey
of methylated candidate tumor suppressor genes in nasopharyngeal
carcinoma. Int J Cancer. 128:1393–1403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li G, Du X, Vass WC, Papageorge AG, Lowy
DR and Qian X: Full activity of the deleted in liver cancer 1
(DLC1) tumor suppressor depends on an LD-like motif that binds
talin and focal adhesion kinase (FAK). Proc Natl Acad Sci USA.
108:17129–17134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qian X, Li G, Asmussen HK, et al:
Oncogenic inhibition by a deleted in liver cancer gene requires
cooperation between tensin binding and Rho-specific
GTPase-activating protein activities. Proc Natl Acad Sci USA.
104:9012–9017. 2007. View Article : Google Scholar
|
|
23
|
Liao YC, Si L, deVere White RW and Lo SH:
The phosphotyrosine-independent interaction of DLC-1 and the SH2
domain of cten regulates focal adhesion localization and growth
suppression activity of DLC-1. J Cell Biol. 176:43–49. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yam JW, Ko FC, Chan CY, Jin DY and Ng IO:
Interaction of deleted in liver cancer 1 with tensin2 in caveolae
and implications in tumor suppression. Cancer Res. 66:8367–8372.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hall EH, Balsbaugh JL, Rose KL,
Shabanowitz J, Hunt DF and Brautigan DL: Comprehensive analysis of
phosphorylation sites in Tensin1 reveals regulation by p38MAPK. Mol
Cell Proteomics. 9:2853–2863. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deng YF, Zhou DN, Ye CS, Zeng L and Yin P:
Aberrant expression levels of MTA1 and RECK in nasopharyngeal
carcinoma: association with metastasis, recurrence, and prognosis.
Ann Otol Rhinol Laryngol. 121:457–465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng N, Li Y, Zhang H and Sun XF: RECK, a
novel matrix metalloproteinase regulator. Histol Histopathol.
23:1003–1010. 2008.PubMed/NCBI
|
|
28
|
Noda M, Oh J, Takahashi R, Kondo S,
Kitayama H and Takahashi C: RECK: a novel suppressor of malignancy
linking oncogenic signaling to extracellular matrix remodeling.
Cancer Metastasis Rev. 22:167–175. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rohan PJ, Davis P, Moskaluk CA, et al:
PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase.
Science. 259:1763–1766. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Q, Muller M, Chen CH, Zeng L, Farooq
A and Zhou MM: New insights into the catalytic activation of the
MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding.
J Mol Biol. 354:777–788. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin SC, Chien CW, Lee JC, et al:
Suppression of dual-specificity phosphatase-2 by hypoxia increases
chemoresistance and malignancy in human cancer cells. J Clin
Invest. 121:1905–1916. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ruan L, Li XH, Wan XX, et al: Analysis of
EGFR signaling pathway in nasopharyngeal carcinoma cells by
quantitative phosphoproteomics. Proteome Sci. 9:352011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wan Y, Yang M, Kolattukudy S, Stark GR and
Lu T: Activation of cAMP-responsive-element-binding protein by PI3
kinase and p38 MAPK is essential for elevated expression of
transforming growth factor beta2 in cancer cells. J Interferon
Cytokine Res. 30:677–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tanioka Y, Yoshida T, Yagawa T, et al:
Matrix metalloproteinase-7 and matrix metalloproteinase-9 are
associated with unfavourable prognosis in superficial oesophageal
cancer. Br J Cancer. 89:2116–2121. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Koskensalo S, Louhimo J, Nordling S,
Hagstrom J and Haglund C: MMP-7 as a prognostic marker in
colorectal cancer. Tumour Biol. 32:259–264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koskensalo S, Mrena J, Wiksten JP, et al:
MMP-7 overexpression is an independent prognostic marker in gastric
cancer. Tumour Biol. 31:149–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Awakura Y, Nakamura E, Takahashi T, et al:
Microarray-based identification of CUB-domain containing protein 1
as a potential prognostic marker in conventional renal cell
carcinoma. J Cancer Res Clin Oncol. 134:1363–1369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ikeda J, Oda T, Inoue M, et al: Expression
of CUB domain containing protein (CDCP1) is correlated with
prognosis and survival of patients with adenocarcinoma of lung.
Cancer Sci. 100:429–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Uekita T, Jia L, Narisawa-Saito M, Yokota
J, Kiyono T and Sakai R: CUB domain-containing protein 1 is a novel
regulator of anoikis resistance in lung adenocarcinoma. Mol Cell
Biol. 27:7649–7660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chou J, Lin YC, Kim J, et al:
Nasopharyngeal carcinoma - review of the molecular mechanisms of
tumorigenesis. Head Neck. 30:946–963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tulalamba W and Janvilisri T:
Nasopharyngeal carcinoma signaling pathway: an update on molecular
biomarkers. Int J Cell Biol. 2012:5946812012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dang CV: Links between metabolism and
cancer. Genes Dev. 26:877–890. 2012. View Article : Google Scholar : PubMed/NCBI
|
